Video Series

A panel of experts discuss the most important goals of therapy for patients with chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma and the largest unmet needs in leukemia/lymphoma.

Brian Koffman, MD, and Callie Coombs, MD, provide the prevalence and incidence rates of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and small lymphocytic lymphoma (SLL), and describe how the diagnosis and management of CLL/MCL/SLL impacts a patient’s quality of life.

Callie Coombs, MD, and Brian Koffman, MD, provide an overview of chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma, and explore the key differences between these disease states.

Cardiovascular risk can be significantly impacted by the presence of diabetes.

Experts highlight key factors when considering costs associated with diabetes treatment pathways.

Dr Haumschild leads a discussion regarding frontline MM treatment products as categorized by NCCN.

Raymond Thertulien, MD, PhD, highlights provider incentives for adherence to MM treatment pathways.

Paige Nues of the International Rett Syndrome Foundation explores the broader effect on a patient’s family members and caregivers.

Rett syndrome significantly impacts both patient and family’s quality of life.

Amy McMichael, MD, and Maria Lopes, MD, MS, review factors to evaluate when starting treatment and how to educate patients on the possible adverse events from that treatment.

Dr Garcia-Manero discusses the effects of TP53 mutation in patients with MDS.

Dr De Castro provides an overview of IV versus oral therapies for patients with PNH.

Omar Nadeem, MD, shares perspective on the significance of collaborative care in the MM treatment landscape.

A panel of experts discuss the value of clinical pathways in MM disease management.

Adequately treating diabetes demands an array of considerations and therapy strategies.

Dr Handelsman drives a conversation surrounding the management of A1C levels.

Medical experts provide their closing thoughts on the chronic obstructive pulmonary disease treatment landscape.

Cost drivers and payer considerations are emphasized for treatment of patients with chronic obstructive pulmonary disease.

A key opinion leader shares considerations for seeking eligibility and enrollment in clinical trials for patients with Rett syndrome.

An expert highlights unmet needs in the treatment of Rett syndrome.

Nonmedication COPD strategies, such as pulmonary rehabilitation, are highlighted.

Selecting appropriate inhalers based on individual characteristics and shared decision-making is crucial for optimizing care for patients with COPD.

Daratumumab can be an effective frontline MM treatment option.

Raymond Thertulien, MD, PhD, discusses high-risk factors for patients with MM.

Key opinion leaders discuss the role of combination therapies in the management of diabetes.

Managing hypertension is a critical aspect of diabetes disease management.

Considerations for insurance preauthorization and reauthorization are explored by a key opinion leader.

Patients and families facing a Rett syndrome diagnosis experience an array of burdens.